Antimicrobial Stewardship
Principles and Practice
by Kerry LaPlante, Cheston Cunha, Haley Morrill, Louis Rice, Eletherios Mylonakis
Description
In an age where antimicrobial resistance amongst pathogens grows more prevalent, particularly in the hospital setting, antimicrobial stewardship is an evidence-based, proven measure in the battle against resistance and infection. This single comprehensive, definitive reference work is written by an international team of acknowledged experts in the field. The authors explore the effective use of coordinated antimicrobial interventions to change prescribing practice and help slow the emergence of antimicrobial resistance, ensuring that antimicrobials remain an effective treatment for infection. Amongst the first of its kind, this book provides infectious disease physicians, administrators, laboratory, pharmacy, nursing and medical staff with practical guidance in setting up antimicrobial stewardship programs in their institutions with the aim of selecting the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. ; Antimicrobial research has hit a wall: treatment discoveries are rarer and resistant pathogen strains more prevalent. Rather than infection control itself, antimicrobial stewardship is an essential measure in ensuring management of hospital-acquired infections. Throughout this book, international experts discuss all angles of stewardship. ; Part I: Overview of Antibiotic StewardshipCh.1: Principles of Antimicrobial StewardshipCh 2: Clinical Perspective of Antimicrobial StewardshipCh 3: History of Antimicrobial StewardshipCh 4: The Importance of Education in Antimicrobial StewardshipPart II: Antibiotic Resistance Principles in Antibiotic Stewardship Ch 5: Intrinsic and Acquired Mechanisms of ResistanceCh 6: Antimicrobial Resistance: Selection vs. InductionCh 7: Colonization and its importance for emergence of clinical resistanceCh 8: Antibiotic Resistance: associations and implications for antibiotic usage strategies to control multi-resistant bacteriaPart III: Microbiology Laboratory Role in Antibiotic StewardshipCh 9: The role of active surveillance in the prevention of healthcare-acquired infections and antibiotic stewardshipCh 10: Role of Antibiogram in Antibiotic StewardshipCh 11: Selective Reporting and Antimicrobial StewardshipCh 12: Role of New Diagnostics to Enhance Antibiotic Stewardship EffortsPart IV: Infection Control Aspects of Antibiotic StewardshipCh 13: Epidemiology of S aureus and enterococci in children and an overview of antimicrobial resistanceCh 14: Epidemiology of multi-drug resistant gram-negative organismsCh 15: Pathogenesis and Epidemiology of Clostridium difficile Infection: Implications for Antibiotic StewardshipCh 16: Role of the Hospital Epidemiologist in Supporting Antimicrobial StewardshipPart V: Pharmacokinetic (PK) & Pharmacodynamic (PD) Aspects of Antibiotic Dosing in Antibiotic StewardshipCh 17: Principles of Pharmacokinetic / Pharmacodynamic Optimization for Antibiotic DosingCh 18: Optimal use of Gram-negative antibiotics in the real world: providing effective therapy while minimizing resistanceCh19: Optimal Use of FluoroquinolonesCh 20: Optimal Use of Beta-lactam AntibioticsCh 21: Current Approach to Optimal Use and Dosing of Vancomycin in Adult PatientsCh 22: Principles of IV to PO SwitchPart VI: Pharmacy Department Role in Antibiotic StewardshipCh 23: Role of Pharmacists in Antimicrobial StewardshipCh 24: Formulary Management and Economic Considerations; Bridging the Gap between Quality Care and CostCh 25: Approaches in benchmarkingCh 26: Development and execution of stewardship interventionsCh 27: Technologic support for antimicrobial stewardshipPart VII: Measuring Outcomes in Antibiotic Stewardship ProgramsCh 28: Role of Guidelines and Statistical Milestones for Antimicrobial StewardshipCh 29: Economic considerations of Antimicrobial Stewardship ProgramsCh 30: Pharmacoeconomic Implications of Antimicrobial Adverse EventsCh 31: Antimicrobial stewardship programs in areas of increased pathogen resistancePart VIII: Antimicrobial Stewardship and Various Practice SitesCh 32: Role of Antimicrobial Stewardship in PediatricsCh 33: Antimicrobial Stewardship in the Intensive Care UnitCh 34: Role of Antimicrobial Stewardship in a Community HospitalCh 35: Outpatient Parenteral Antimicrobial Therapy (OPAT)Ch 36: The Importance of Interdisciplinary Collaboration in Antimicrobial Stewardship: Immersion of Future Healthcare ProfessionalsCh 37: Antimicrobial Stewardship and the Importance of Working with the Government and Pharmaceutical IndustryCh 38: Hospitalist Perspective on the Role of Antimicrobial Stewardship
More Information
Rights Information
Foreign rights available. We will positively consider translations of abridged versions of this title. If you wish to receive image and/or design files, please let us know at the beginning of the process and when making an offer. CABI reserves the right to charge an additional fee for such requests, which will be added to the overall fee, and to refuse such requests if the files are not available or for any other reason.
Author Biography
is a physician-scientist and his work focuses on the study of microbial pathogenesis and drug discovery. His research has developed a novel alternative to studying bacterial and fungal infection and host responses: the use of invertebrate model hosts. These surrogate invertebrate hosts fill an important niche in fungal pathogenesis research. His investigations have identified novel virulence factors, cross kingdom pathogen-pathogen interactions, novel antifungal agents and evolutionarily conserved traits that are involved in host virulence and immune responses during infection. Recently, Dr. Mylonakis implemented high-throughput whole-animal Caenorhabditis elegans assay to screen libraries of chemical compounds and identify those with antimicrobial activity. In vivo evaluation of libraries of chemical compounds could solve some of the main obstacles in current antifungal discovery, such as finding new classes of compounds and solving the bottleneck of toxicity/efficacy testing. This a
CABI (CAB International)
CABI (CAB International) is an international, non-profit body improving lives by providing information & scientific expertise to solve problems in agriculture & the environment.
View all titlesBibliographic Information
- Publisher CAB International
- Publication Date December 2016
- Orginal LanguageEnglish
- ISBN/Identifier 9781780644394 / 1780644396
- Publication Country or regionUnited Kingdom
- FormatHardback
- Primary Price 150 GBP
- Pages450
- ReadershipProfessional and Scholarly
- Publish StatusPublished
- Copyright Year2016
- Dimensions246 X 189 mm
- Reference Code3455
CABI (CAB International) has chosen to review this offer before it proceeds.
You will receive an email update that will bring you back to complete the process.
You can also check the status in the My Offers area
Please wait while the payment is being prepared.
Do not close this window.